已收盤 11-20 16:00:00 美东时间
-0.493
-2.54%
Allarity Therapeutics expands eligibility for its Phase 2 stenoparib trial in advanced ovarian cancer to include patients with primary platinum-refractory disease and those with hard-to-measure but clinically evaluable disease. This expansion follows encouraging early results, including durable clinical benefit and extended survival, and aims to evaluate stenoparib's potential across a broader patient population. The trial now includes three pati...
11-16 12:50
Sutro Biopharma reported progress in its ADC pipeline, with STRO-004 and STRO-006 entering clinical trials and STRO-227 advancing toward early 2027 development. The company also received a $10 million milestone payment from Astellas for initiating a second dual-payload iADC program. Sutro's cash reserves of $142.2 million are expected to support operations into 2028. CEO Jane Chung highlighted the potential of the company's ADC platform to delive...
11-12 21:30
Iovance Biotherapeutics reported a record third quarter 2026 with ~$122 million in revenue, up 80% year-over-year, and a gross margin of ~60%. U.S. Amtagvi revenue grew 77% YoY to ~$102 million. The company achieved a 24.6% objective response rate (ORR) in 69 patients with non-squamous metastatic non-small-cell lung cancer (mNSCLC) and a 59.1% ORR in a biomarker-selected subgroup. The SARATOGA trial for undifferentiated pleomorphic sarcoma (UPS) ...
11-05 12:00
Aprea Therapeutics reported Q3 2026 financial results with $37.8 million in cash and provided updates on its WEE1 inhibitor APR-1051, which is advancing in a Phase 1 clinical trial expanded to nine sites. The company plans to present interim Phase 1 data at the EORTC-NCI-AACR Symposium in November 2026 and expects to select the dose for Part 2 in early 2027. APR-1051 is being evaluated in biomarker-defined cancers, with a focus on endometrial can...
11-04 13:30
Iovance Biotherapeutics announced that lifileucel monotherapy achieved a 50% confirmed ORR in a pilot trial for metastatic UPS and DDLPS at the ESMO Congress 2026. All four partial responses were ongoing as of September 2026. The safety profile was consistent with previous studies, and the FDA granted fast track designation for lifileucel in advanced UPS and DDLPS. The SARATOGA trial is now enrolling patients to support new approvals, highlightin...
10-26 11:00
Zentalis Pharmaceuticals announced interim OS data from the DENALI Part 1b study for azenosertib in platinum-resistant ovarian cancer (PROC). Cyclin E1-positive patients (n=48) had a median OS of 15.8 months, compared to 7.5 months in Cyclin E1-negative patients (n=46). No new safety signals were observed. The data will be presented at the ESMO Congress 2026 on October 23. Azenosertib is being further developed in DENALI Part 2 and the ASPENOVA P...
10-18 22:05
Apple Inc (NASDAQ:AAPL) stock gained almost 3% on Wednesday as buyers lean into large-cap strength despite a softer tape in Technology. The Nasdaq is up 0.13% while the S&P 500 has gained 0.53%, even as the Technology sector is down 0.6%. The Big Tech giant is balancing regulatory changes in Europe,...
08-20 00:34